Hyftor (Sirolimus) Patent Expiration, LOE Window & CMS Spending

Hyftor (Sirolimus) by Nobelpharma: FDA Orange Book LOE 2045-04-11, 4 AB generics, $7.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNobelpharma
FDA Application & PathwayN213478 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2045-04-11
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$7.9M
2024 Medicare Part D Spend$1.4M
2024 Medicaid Spend$6.5M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel